Sotagliflozin not checked
Lexicon Pharmaceuticals · SAR439954 · SAR439954/LX4211
FollowEvery change as it happens, and a Monday email
Trials
4 active
16 in total · 4 in the EU
What this is
- How it works
- Makes the kidneys flush extra sugar and salt into the urine. Started as a diabetes drug; now also used for heart and kidney disease.Sodium-Glucose Cotransporter 2 Inhibitor FDA class
- How it’s given
- “Sotagliflozin will be administered as a tablet(s), orally once daily.”In the company’s words, NCT06481891 on ClinicalTrials.gov
- Tested for
- Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
- Main trialPhase 3
- “The main purpose of the study is to determine the changes in symptoms and functional limitations in participants with symptomatic hypertrophic cardiomyopathy (HCM) treated with sotagliflozin as compared to placebo.”In the company’s words, NCT06481891 on ClinicalTrials.gov
- Other names
- SAR439954 · SAR439954/LX4211
Other drugs for Non-obstructive Hypertrophic Cardiomyopathy
- HRS-1893Hengrui · Phase 3
- BHB-1893Braveheart Bio, Inc. · Phase 3
- AficamtenCytokinetics · Phase 2/3
- BAY3723113Bayer · Phase 3
- NinerafaxstatImbria Pharmaceuticals, Inc. · Phase 2
- QG101-23-0Amckaus PTY LTD. · Phase 2
Coming up1
- Jan 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials16
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Jan 2027 | A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy | |
| Phase 3Completed | 26 Feb 2019 | Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin | |
| Phase 3Completed | 25 Mar 2019 | Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control | |
| Phase 3Completed | 17 Apr 2019 | Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin | |
| Phase 3Completed | 22 Apr 2019 | Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy | |
| Phase 3Completed | 16 May 2019 | Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin | |
| Phase 3Completed | 16 May 2019 | A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control | |
| Phase 3Terminated | 22 May 2019 | Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control | |
| Phase 3Completed | 6 Aug 2019 | Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy | |
| Phase 3Completed | 17 Sep 2019 | Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents | |
| Phase 3Terminated | 5 Jun 2020 | Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial) | |
| Phase 3Terminated | 8 Jul 2020 | Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk | |
| Phase 2Terminated | 17 Aug 2019 | Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure | |
| Phase 3Authorised | not given | Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes | |
| Phase 2Authorised | not given | Sotagliflozin for the treatment of post-bariatric hypoglycaemia: The ONSIDE study | |
| Phase 2Authorised | not given | Prevention of CKD progression in type 1 diabetes with Long term Use of SGLTi avoiding kidney hypOxia (PLUTO) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026